Catalyst Pharma Reveals Pioneering Research at Conferences
Catalyst Pharmaceuticals will present new real-world evidence across Duchenne muscular dystrophy and Lambert-Eaton myasthenic syndrome at major neuromuscular meetings...
New ‘Moms Against Molluscum’ Movement Unites Families
Pelthos Therapeutics has launched “Moms Against Molluscum,” a caregiver-focused movement and website designed to elevate awareness of molluscum contagiosum...
Introducing Beghou ARC: A New Platform for Life Sciences
Beghou has launched ARC, a connected commercialization platform designed to unify data, technology, and field execution into a single...
Gelteq, Melbourne Health Partner on Bowel Polyp Compound
Gelteq has signed a product development and profit‑sharing agreement with Melbourne Health, operator of the Royal Melbourne Hospital, to...
New Hope: Rein’s IPF Drug Gets EU Approval for Phase 2 Trial
Rein Therapeutics has secured authorization from the European Medicines Agency to initiate the Phase 2 RENEW trial of LTI-03...
Assembly Bio Presents Promising New Interim HSV Drug Data
Assembly Biosciences reported interim Phase 1b results for its long-acting HSV helicase-primase inhibitor ABI-5366, presented as a late-breaking oral...
60 Degrees Pharma Unveils B-FREE Chronic Babesiosis Study
60 Degrees Pharmaceuticals will initiate B-FREE, a Phase 2 open-label study of tafenoquine (marketed as Arakoda for malaria prophylaxis)...
FDA Approves Lasix® OnYu for At-Home Heart Failure Edema
FDA has approved Lasix Onyu, a subcutaneous, high‑concentration furosemide drug–device combination for treating edema due to fluid overload in...
FDA Approves Jascayd, First New IPF Drug in Over a Decade
Boehringer Ingelheim has secured FDA approval for Jascayd (nerandomilast), an oral, first-in-class preferential PDE4B inhibitor for adults with idiopathic...
Novo Nordisk’s MASH Breakthrough: Acquires Akero Therapeutics
Novo Nordisk has agreed to acquire Akero Therapeutics for $54 per share in cash, or roughly $4.7 billion at...